Question 1

Should I switch from Trulicity to Mounjaro?

Accepted Answer

For most adults with type 2 diabetes who need additional A1C lowering or meaningful weight loss, yes — Mounjaro is the stronger molecule on every glycemic axis. Cross-trial data show Mounjaro 15 mg lowers A1C by roughly 2.3% and body weight by ~11-12 kg, versus Trulicity 1.5 mg's ~1.1% A1C and ~3 kg. The switch is typically restart at Mounjaro 2.5 mg regardless of prior Trulicity dose, then titrate every 4 weeks. Stay on Trulicity if you specifically need its cardiovascular-risk-reduction label (REWIND, PMID 31189511) or the pediatric indication.

Question 2

Why is Trulicity still prescribed if Mounjaro is more effective?

Accepted Answer

Three reasons. First, Trulicity has a finished cardiovascular outcomes trial (REWIND) showing a 12% reduction in major adverse cardiovascular events — Mounjaro's SURPASS-CVOT will not read out until 2027. Second, Trulicity carries an FDA pediatric indication for type 2 diabetes in ages 10 and older; Mounjaro is adult-only. Third, the AWARD-7 trial (Tuttle 2018, PMID 29910024) established dulaglutide as a viable GLP-1 in moderate-to-severe chronic kidney disease — Mounjaro's CKD evidence is thinner. Insurance formularies still favor Trulicity in many T2D + CV-disease patients.

Question 3

Is Mounjaro safe for kids?

Accepted Answer

Mounjaro is not FDA-approved for pediatric use. The Mounjaro label restricts use to adults aged 18 and older — there are no pediatric efficacy or safety data filed with the FDA. Trulicity holds the only weekly-injectable GLP-1 pediatric T2D indication (ages 10+, approved 2022). For an adolescent who needs a GLP-1 for diabetes, Trulicity is the labeled option; for obesity in adolescents aged 12+, Wegovy and Saxenda are the labeled choices. Off-label pediatric Mounjaro is rarely covered and is not recommended outside investigational settings.

Question 4

Does Mounjaro have CV data like REWIND?

Accepted Answer

Not yet. REWIND (Gerstein 2019 Lancet, PMID 31189511) randomized 9,901 adults with T2D — most without established CV disease — to Trulicity 1.5 mg or placebo over a median 5.4 years and showed a 12% reduction in the composite MACE outcome (HR 0.88, p=0.026). Mounjaro's dedicated cardiovascular-outcome trial, SURPASS-CVOT, is comparing tirzepatide head-to-head against dulaglutide and is expected to report in 2027. Until then, Trulicity is the only Lilly GLP-1 with an FDA-approved CV-risk-reduction indication.

Question 5

Why use Mounjaro instead of Zepbound — they're the same molecule?

Accepted Answer

Pharmacologically they are identical (both tirzepatide, same doses, same pens). The split is regulatory: Mounjaro carries the FDA type 2 diabetes label, so commercial insurance covers it for T2D patients with A1c ≥6.5% and a documented metformin trial. Zepbound carries the obesity and obstructive sleep apnea labels — many plans exclude obesity drugs entirely, leaving patients paying cash. If you have T2D, Mounjaro routes through the diabetes benefit and is usually cheaper through insurance. If you do not have T2D, Zepbound through LillyDirect ($349-$499/mo vial) is the legitimate path.

Question 6

Are the side effects different between Trulicity and Mounjaro?

Accepted Answer

Both share the GLP-1 GI side-effect profile (nausea, diarrhea, vomiting, constipation, decreased appetite), but Mounjaro's rates run higher because the doses produce larger peak effects. In SURPASS-2, Mounjaro 15 mg caused nausea in ~22% of patients vs Trulicity's typical ~12-21% range across AWARD trials. Both labels carry the same FDA boxed warning for thyroid C-cell tumors observed in rodents, and both carry warnings for pancreatitis, gallbladder disease, and acute kidney injury via dehydration. Titrate slowly to minimize GI tolerability problems.

Field	Trulicity	Mounjaro
Mechanism	GLP-1 receptor agonist	Dual GIP / GLP-1 receptor agonist
A1C reduction (max dose, cross-trial)	−1.1% / 26 wk (Trulicity 1.5 mg, AWARD program)	−2.30% / 40 wk (Mounjaro 15 mg, SURPASS-2)
Weight loss (max dose, cross-trial)	−2.9 to −3.1 kg / 26 wk (Trulicity 1.5 mg)	−11.2 kg / 40 wk (Mounjaro 15 mg, SURPASS-2)
Insulin-comparator head-to-head	No direct insulin-degludec head-to-head at max dose	−2.37% A1C vs insulin degludec −1.34% (SURPASS-3, 52 wk)
Dosing	Once-weekly subq 0.75 → 1.5 → 3 → 4.5 mg pen	Once-weekly subq 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg
FDA-approved indication	Type 2 diabetes (adults + pediatrics ≥10); CV risk reduction in T2D	Type 2 diabetes (adults only)
Cardiovascular outcome	MACE −12% (REWIND, HR 0.88; in T2D ± established CVD)	SURPASS-CVOT readout pending 2027
Pediatric T2D label	Approved ages 10 and older (since 2022)	Not approved in pediatrics
Cash price (manufacturer / retail, ~2026)	~$987/mo retail; Lilly Cares + commercial savings card	~$1,069/mo WAC; LillyDirect savings card (commercial only)

Trulicity vs Mounjaro (2026): Lilly's Old vs New Weekly T2D Shot

The verdict

Side-by-side comparison

Frequently asked questions